The document provides an overview of the oncology drug market. It discusses that the global cancer drug market was valued at $112.9 billion in 2016 and is expected to reach $161.3 billion by 2021, growing at a CAGR of 7.4%. Blood cancer accounts for the largest segment of the market. The top 3 companies, Roche, Novartis, and Amgen, have a combined market share of 56% and their blockbuster drugs are discussed. The Indian oncology drug market was worth INR 3831 crores in 2016 and is growing at 15.46% annually. Breast, lung, and cervical cancers account for over 50% of cancer deaths in India currently.
2. INTRODUCTION
Cancer is defined as a disease which occurs as a result of changes in group of normal cells with in the body which leads
uncontrolled growth resulting in formation of tumours (except blood cancer).
MARKET SIZE
Cancer drug market was valued at US 112.90 billion in 2016 and is expected to grow US 161.30 billion by the end of
2021,growing at a CAGR of 7.4% between 2016-21.
37%
28%
5%
6%
18%
2%4%
CANCER TYPES
BLOOD CANCER
BREAST CANCER
GASTRO INTESTINAL
CANCER
PROSTATE CANCER
RESPIRATORY
SKIN
Geographically, North America, dominates the market followed by Europe.
North America accounted for about 40% share in the overall oncology drugs
market in 2016.
Blood cancer segment dominated the market.
INDIAN CANCER MARKET SIZE
Indian oncology market is INR 3831 Cr. in 2016 at a CAGR of 15.46
percent.
Cancers of oral cavity and lungs in males, and cervix and breast in females,
account for over 50 percent of all cancer-related deaths in India at present.
In India, there are 28 lakh prevalent cases of all types of cancer, while at least
8 lakh new cases are being witnessed every year.
5/29/2017 2
3. TOP 3 KEY PLAYERS IN INTERNATIONAL MARKET(BRAND)
Company ROCHE NOVARTIS AMGEN
THEME “PIECING TOGETHER THE BIG
PICTURE FOR THE FUTURE”
“NO PIPELINES JUST PIPE
DREAMS”
“POWER TO RESTORE LIVES”
MARKET SHARE 29% 18% 9%
REVENUE 28.8$ US BILLIONS 14.3$ US BILLIONS 7.9$ US BILLIONS
BLOCKBUSTER DRUGS AVASTIN-6.8%.
HERCEPTIN-6.6%
RITUXAN-6.3%
TARCEVA-1.4%
XELODA-1.6%
ZELBORAF-0.4%
KADEYLA-0.5%
PERJETA-0.3%
GLEEVAC-4.7%
SANDOSTATIN-1.6%
AFINITOR-1.5%
TASIGNA-1.5%
EXJADE-0.9%
FEMARA-0.4%
KYPROLIS-3.2%
NEUPOGEN-1.4%
NEULASTA-1.3%
BLISCYTO-1.1%
XGEVA-0.3%
SEGMENTATION, TARGETING ,POSITIONING:
Segmentation is done by the 1.types of cancer,
2.therapy of cancer
1.Immuno therapy(14%) 5.surgery(20%)
2.Targeted therapy(18%) 6.others.
3.Chemo therapy(39%)
4.Hormone therapy(6%)
5/29/2017 3
4. MARKET ENTRY STRATEGY
COST-SHARING STRATEGY.
RISK SHARING STRATEGY.
PAYMENT BY PERFORMANCE.
TARGETING BY GENDER
WOMEN MEN
Breast 32%*
Lung & Bronchus 12%
Colon & Rectum 11%
Uterine Corpus 6%
Ovary 4%
Non-Hodgkin Lymphoma 4%
Melanoma of the Skin 4%
*Prostate 33%
Lung & Bronchus 13%
Colon & Rectum 11%
Urinary Bladder 6%
Melanoma of the Skin 4%
Non-Hodgkin Lymphoma 4%
Kidney 3%
TARGETING BY RISK
1.Smokers
2.Second Hand Exposure
3.Occupational Exposure
POSITIONING THE BRAND
1.valued segments
2.value proportion
3.value network
“Patient experience is strategy-critical”
COMPANY ROCHE DR.REDDY’S NATCO PHARMA
THEME “PIECING TOGETHER THE BIG
PICTURE FOR THE FUTURE”
“GOOD HEALTH
CAN’T WAIT”
“MAKING SPECIALITY MEDICINES
ACCESIBLE TO ALL”
MARKET SHARE 23% 18% 12%
MARKET REVENUE 869 INR CRORES 680.58 INR CRORES 374 INR CRORES
BLOCKBUSTER
DRUGS
AVASTIN
HERCEPTIN
RITUXAN
Oxaliplatin
Reditux
Lenangio
SORAFENAT
GEFTINAT
VEENAT5/29/2017 4
5. QUESTIONNAIRE TOWARDS DISTRIBUTION
WHAT IS THE MECHANISM OF DISTRIBUTION?
WHAT ARE THE PRICE AND PAYMENT OPTIONS?
AS CANCER PRODUCTS ARE QUIET EXPENSIVE DO YOU PROVIDE ANY PRICE DISCOUNTS?
HOW MANY REGIONAL WAREHOUSES DID COMPANY HAVE?
“DOCTORS CALLS THE DISTRIBUTOR/ SALES REPRESENTATIVE FOR DRUGS …
THAT IS THE ONLY THING THAT HAPPENS IN ONCOLOGY SEGMENT”
5/29/2017 5
6. TIERS OF DISTRIBUTION/TYPES OF TRADE MARGIN
Distribution type used is cold chain distribution.
The software used to operate the data is SAP.
Every company have the regional warehouses from the drugs get transported to its final customer.
For the distribution of the drugs the companies utilizes the services of air cargo with definite time and temperature
requirements
BARRIERS TO COMMUNICATION IN SCM.
As we are in the era of digitalization at present there are very minute barriers in communicating.
Picture 1
5/29/2017 6
7. DATAANALYSIS AND INTERPRETATION
The survey was conducted in JUBILEE HILLS,BANJARA HILLS and SEC.BAD to have a better view of
management of cancers.
Doctors managing cancers are:
Medical Oncologists
Surgical Oncologists
Radiation Oncologists
Urologists
QUESTIONNAIRE TO PHYSICIAN
1.What is your preferred treatment option for xxxx cancer patients?
1.Immuno therapy(14%) 5.surgery(20%)
2.Targeted therapy(18%) 6.others.
3.Chemo therapy(39%)
4.Hormone therapy(6%)
2.What are the top three medications you prescribe to the patient?(breast cancer)
1.armidex(DR.REDDY’S)-31%
2.anastronat(NATCO PHARMA)-41%
3.Herceptin(ROCHE)-28%
Target Group J.HILLS B.HILLS SECUNDRABAD
Med Oncos 1 1 1
Sur Oncos 1 1 -
Rad Oncos 1 - 1
Uros 2 - 1
Total 5 2 3
5/29/2017 7
8. • 3.What type do patients prefer?
A.LONG ACTING ORAL DOSAGE FORMS (45%)
B.INJECTION FORMS(20%)
C.RADIATION TREATMENT
D.SURGERY (20%)
• 4.In your practice what would be the median age of a newly diagnosed xxxx cancer patient?
A.20-30(9%)
B.30-40(35%)
C.40-50(30%)
D.>50.(25%)
• 5.In your practice out of total xxxx cancer patients,what is the percentage of patients in each state?
0.09
0.19
0.3
0.42
0.07 0.08
0.13
0.72
0
0.1
0.15
0.75
0.08
0.14
0.38 0.4
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Stage I Stage II Stage III Stage IV
%ofpatients
Radiation Oncologists Surgical Oncologists Medical Oncologists Urologists
5/29/2017 8